Hydrochlorothiazide/nebivolol hydrochloride

Drug Profile

Hydrochlorothiazide/nebivolol hydrochloride

Alternative Names: Conébilox; HCTZ/nebivolol; Hydrochlorothiazide/nebivolol; Hypoloc-plus; Hyporetic; Lobidiur; Nebilet Comp; Nebilet Plus; Nebilet Plus H; Nebivolol hydrochloride/hydrochlorothiazide; Nebivolol plus HCTZ; Nebivolol/HCTZ; Nebivolol/hydrochlorothiazide; Nebizide; Nomexor plus HCT; Silostar Plus

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Menarini
  • Class Antihypertensives; Benzopyrans; Benzothiadiazines; Ethanolamines; Fluorobenzenes; Heart failure therapies; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 22 Feb 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top